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ABSTRACT
Objective: The evaluation of peripheral vascular disease in the primary
care setting is routinely performed by contrast-enhanced magnetic reso-
nance angiography (CE-MRA) and digital subtraction angiography (DSA).
However, limited data are available on the relative costs and clinical
outcomes following these diagnostic procedures. The objective of this
study is to assess and compare costs associated with diagnostic imaging in
peripheral vascular occlusive disease (PAOD).
Methods: US veterans (n = 19,209) with CE-MRA or DSA for the assess-
ment of PAOD from ﬁscal year (FY) 1999 to FY 2004. Main outcome
measure(s) using the Department of Veterans Affairs’ (VA) costing algo-
rithms, cost, and log-cost of interventions (e.g., revascularization, stent,
angioplasty), amputations or mortality rates within 30/90 days and 1 year
of DSA or CE-MRA were compared, and adjusted for patient character-
istics and disease severity using multivariate regression. Imaging modality
selection bias was evaluated with propensity score, instrumental variables,
and Heckman methods using untransformed costs and log-costs with
smearing retransformation.
Results: Initial CE-MRA imaging was signiﬁcantly more likely among
patients with prior renal disease or bypass surgery [odds ratio (OR) > 2;
P < 0.001], and less likely among patients with prior amputation, periph-
eral vascular disease (PVD), claudication, or other cardiovascular disease
(OR < 0.7; P < 0.001). After adjusting for endogenous choice of initial
imaging modality, 30-day treatment costs were US$3500–$4300 lower
(P < 0.001) for patients with initial CE-MRA. Eighty-two percent of DSA
imaging patients had no additional procedures or events within 30 days,
and 65% at 90 days. Less than 3.2% (3.6%) of patients had any repeat
imaging within 30 (90) days of initial imaging.
Conclusions: Relative to DSA, CE-MRA imaging was associated with
substantial treatment episode savings, beyond the US$950 direct savings in
imaging cost per procedure. Substituting CE-MRA for DSA among those
not planning or requiring any follow-up procedures within 30 days, could
have reduced outpatient imaging costs by up to 55%, and reduced VA
system costs by US$13.2 million over the six-year period.
Keywords: contrast-enhanced magnetic resonance imaging, diagnostic
imaging, digital subtraction imaging, peripheral vascular disease, VA treat-
ment costs.
Introduction
In 2005, approximately 80million advanced diagnostic radiology
examswere conducted in the United States. The cost for these tests
was approximately US$100 billion, up from about $75 billion in
2000 [1]. Diagnostic imaging services have shown the highest
cumulative rate of growth of all Medicare services over the
1999–2003 period [2]. Of these diagnostic imaging services,
Magnetic Resonance Imaging (MRI) for body sites other than the
brain had the highest rate of growth of all Medicare imaging
procedures. Nevertheless, MRI has the smallest share of the
imaging market. In 2002, MRI scans accounted for only 6.5% of
total US imaging procedures and are projected to rise to 12% in
2008 [3].
Angiography uses one of three imaging technologies and, in
some cases, a contrast material to image the major blood vessels
throughout the body. Angiography is performed using: 1) an
invasive procedure—x-rays with catheters (digital subtraction
angiography or DSA); 2) computed tomography (CT); or 3)
MRI. In magnetic resonance angiography (MRA), magnetic ﬁeld,
radio waves, and a computer produce the detailed images. MRA
is noninvasive and does not use ionizing radiation (x-rays). MRA
may be performed with or without contrast material.
Despite the rapid and expensive growth in imaging services,
there are few published cost effectiveness analyses regarding the
use of these services, and there is little information on the impact
of alternative diagnostic imaging modalities on patient clinical
outcomes or costs. Most of the existing literature on MRA versus
DSA is based on relatively small patient samples and short-term
follow-up, with modeling techniques used to evaluate more
long-term costs and outcomes [4,5]. The American College of
Radiology has developed appropriateness criteria for a number
of common presentations, and recommendations for tests that
have been found to be particularly effective and tests that are not
as effective. Nevertheless, third party payers have not generally
incorporated such evidence-based medicine criteria into reim-
bursement policies [6].
One example of the growing use of imaging is in the evalu-
ation of patients presenting with suspected peripheral artery
occlusive disease (PAOD). Studies assessing the cost effectiveness
of both contrast-enhanced MRA (CE-MRA) and DSA, are
limited in nature and are generally based on small clinical studies
to evaluate the imaging precision of either testing strategy [7–9].
These studies have generally shown MRA to be cost effective
relative to DSA. However, there is little evidence linking the
clinical impact of either modality as a screening procedure to
guide treatment interventions among patients with PAOD. Visser
et al. [7] found that MRA is cost effective compared with DSA
for less invasive surgery patients, but DSA is cost effective com-
pared with MRA for invasive surgery patients. However, quality-
adjusted life-year differences (0.0011 less invasive; 0.0118
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invasive) and the cost differences ($690 less invasive; $229 inva-
sive) were quite small. We are not aware of any studies that have
evaluated cost differences between these imaging procedures in
large multiyear patient populations.
This study aims to evaluate medical treatment costs associ-
ated with the patterns of diagnostic imaging of the lower extrem-
ity for patients initiating either DSA or CE-MRA in the
ambulatory care sector. The study evaluates the relative costs of
complications because of imaging with each diagnostic modality,
and the treatment costs for lower extremity interventions follow-
ing imaging.
Methods
Data Sources
This retrospective cohort study approved by the Institutional
Review Board (IRB) of the US Veterans Administration Boston
Healthcare System uses data from the Veterans Health Adminis-
tration’s National Patient Care Database, which contains the
Patient Treatment Files (PTF) and Outpatient Clinic (OPC) ﬁles.
PTF represents patient hospitalizations and OPC ﬁles represent
visits to the Veterans Administration Healthcare system.
Study Population/Sample Size
Using the national database, we identiﬁed all users of the
Veterans Administration Healthcare System who underwent
outpatient lower extremity imaging, either DSA or CE-MRA
[International Classiﬁcation of Diseases (ICD)-9 codes: 88.48
and 00.23; Current Procedural Terminology (CPT) codes: 75716,
75630, and 73725]. First imaging procedure was deﬁned as the
primary imaging procedure used for the diagnosis or assessment
of Peripheral Artery Occlusive Disease [PAOD (ICD-9 code:
443.9)]. We collected information about demographics [age,
gender, race, and Veterans Affairs (VA) clinic site], patient
medical history covariates, Charlson comorbidity index scores,
complications occurring within 30 days of imaging, lower
extremity interventions within 1 year of ﬁrst imaging procedure,
and death following imaging.
Our ﬁnal sample included 19,209 (94.4%) of the 20,343
users of the VA Healthcare system, who underwent diagnostic
lower extremity imaging procedures (either MRA or DSA)
between October 1, 1998 [start of ﬁscal year (FY) 1999] and
September 30, 2005 (end of FY2005). All subjects of the cohort
used the Veterans Administration Healthcare system between the
years FY1999 and FY2005. To ensure that we had at least one
year’s follow-up from the index date of diagnosis, we only
included patients with an initial diagnosis date during or before
FY2004. We excluded 1134 subjects from the original dataset
because they did not have one year’s follow-up after the primary
lower extremity imaging procedure.
To describe the patterns of lower extremity imaging proce-
dures for the diagnosis of PAOD, we categorized the cohort
into two groups based on the primary imaging procedure,
either MRA or DSA. We required patients to have 12 months
of VA utilization without history of MRA prior to any incident
MRA, to identify “new” imaging procedures courses of care.
We also required 12 months of follow-up postimaging, to
better assess any potential complications, to ensure the patient
was not transferred out of the system postimaging. The Charl-
son comorbidity index is time sensitive, and we used a 365-day
look-back incorporating both inpatient and outpatient diagnos-
tic and procedure data to ensure that we obtained complete
capture of Charlson criteria, and did not engineer any bias
because of a differential follow-up in the system. Disease
covariates were identiﬁed using a minimum of 12 months of
follow-up; however, we used the breadth of the database to
characterize duration of chronic disease conditions of interest.
Sensitivity analyses using 12-month windows of look-back do
not produce meaningful differences in disease estimates versus
using longer windows.
PAOD Treatment Event Costs
The primary outcomes of interest in this study were medical costs
associated with lower extremity revascularization or surgical
interventions, repeat imaging procedures, complications within
30 days, and death following imaging procedure. Comparison of
differences in practice patterns, and clinical outcomes associated
with the two imaging modalities are described elsewhere [10].
Interventions included Percutaneous Transluminal Angio-
plasty [PTA, (ICD-9 code: 39.50; CPT codes: 75962, 75964)],
stent (ICD-9 code: 39.90; CPT code: 75960), bypass surgery
(ICD-9 code: 39.25, 39.29; CPT codes: 35582, 35583, 35585,
35587), and amputations (ICD-9 codes: 84.1, 84.12, 84.17,
84.10, 84.11, 84.15, 84.14). Repeat imaging procedures included
both MRA and DSA imaging (ICD-9 codes: 88.48, 00.23; CPT
codes: 75716, 75630, 73725). Allergies due to radiologic dye
(ICD-9 code: V15.08), hematomas (ICD-9 code: 996.62), vascu-
lar (ICD-9 code: 997.2), and renal complications (ICD-9 codes:
584.9, 580–583.9), were documented as complications.
Patient Demographic and Medical History Covariates
With regard to practice pattern differences, we measured baseline
characteristics such as baseline age, race, and gender along with
information on the following disease covariates: diabetes mellitus
(ICD-9 code: 250–250.9), hypertension (ICD-9 code: 401,
401.01, 401.1, 401.9), cardiovascular disease (ICD-9 codes:
00.66, 36, 410–414), baseline peripheral vascular disease (ICD-9
code: 443.9), chronic renal disease (ICD-9 code: 585.9), athero-
sclerosis of extremities with intermittent claudication (ICD-9
code: 440.21), and baseline revascularization or surgical inter-
ventions for peripheral vascular disease (PTA or stent or bypass
or amputation; ICD-9 codes speciﬁed earlier). We also captured
baseline Charlson comorbidity index scores for sample patients
[11].
Cost Measurement
We used VA average costs per procedure to assess the medical
care costs associated with imaging modalities and the follow-on
procedures identiﬁed above. We excluded costs for treatment of
comorbidities or other medical events that were clearly unrelated
to the initial imaging procedure. We used US dollar costs from
the national VA data for FY2004 because it was the most current
year available with complete prices and because there was
nothing indicating that the 2003 estimates were a better basis for
our cost estimates (e.g., procedure frequencies were not greater in
2003, the variation in costs was not less, combining the 2 years
did not reduce variation, etc.).
Data Analysis
Initial imaging modality selection is subject to endogenous treat-
ment selection bias [12]. Patients presenting with the highest
PAOD symptom severity levels would be more likely to receive
DSA rather than CE-MRA because this would allow the treating
physician to initiate an immediate or emergency vascular proce-
dure if necessary. Similarly, patients presenting with renal disease
would be more likely to receive CE-MRA because the DSA
imaging contrast agents are more likely to lead to complications
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in renal patients. It was clear from the evaluation of the des-
criptive statistics regarding patient demographics and medical
histories that there were substantial differences in patient char-
acteristics between those patients choosing CE-MRA or DSA as
the initial outpatient imaging modality [10]. In order to adjust
for both observable and unobservable characteristics that could
confound and bias the effect of initial imaging modality on
treatment cost differences, we used the Heckman selection bias
and instrumental variables estimates of the CE-MRA and DSA
cost differences, as well as simple OLS multivariate regression
estimates with and without propensity score adjustments [12].
Because we didn’t have any explanatory variables that were
plausible instruments themselves (i.e., that could plausibly be
excluded from the cost equation but not from the treatment
choice equation), we used the ﬁtted propensity score as an instru-
ment for the endogenous binary treatment choice variable
[CE-MRA vs. DSA as the initial diagnostic procedure]. The pro-
pensity score method and the Heckman selection bias methods
involved adding, respectively, the additional regressors pi (the
ﬁtted propensity score from Table 2) and -fi/pi (the ﬁtted inverse
Mills ratio based on the probit treatment selection equation
(available from the authors upon request). For the instrumental
variables estimates, the ﬁtted propensity scores and inverse Mills
ratios are included as instruments for the endogenous treatment
selection variable. We also ran models using log-transformed
costs with Smearing estimates of the standard errors for retrans-
formation as a robustness check on the untransformed cost
regression models.
Results
Patient Descriptive Statistics
In the years 1999 through 2005, 19,209 patients underwent an
initial diagnostic imaging procedure at a VA facility. Of these
patients, 3183 underwent MRA as the ﬁrst imaging procedure
and 16,026 underwent DSA as the ﬁrst imaging procedure.
Table 1 describes the differences between the MRA and DSA
groups in baseline characteristics.
The proportion of patients undergoing a second imaging
procedure within 1 year was low (CE-MRA, 9.6%; DSA, 6.6%).
The proportion with repeat imaging 30 days/90 days after the
initial diagnostic procedure was very low (CE-MRA, 3.1%
30-day/5.5% 90-day; DSA, 1.3% 30-day/2.5% 90-day). The
percentage of patients with any additional procedures or events
within 30 days/90 days was also low (CE-MRA, 8% 30-day/
24% 90-day; DSA, 18% 30-day/35% 90-day).
Table 1 Baseline characteristics of patients in the Veterans Affairs Healthcare System by the type of lower extremity imaging procedure
Characteristic CE-MRA N = 3183 DSA n = 16026 P value
Age, years 64.13 12.34 65.14 9.90 <0.0001
Men 96.73 98.75 <0.0001
Diabetes Mellitus 39.15 39.25 0.9132
Cardiovascular disease 58.0 68.1 <0.0001
Documented history of PVD (Baseline PVD + Claudication) 71.7 89.7 <0.0001
History of prior angioplasty, stent, bypass amputation 9.1 18.8 <0.0001
Chronic Renal Disease 12.9 5.6 <0.0001
Hypertension 76.5 80.2 <0.0001
Race <0.0001
Caucasian 59.9 70.9
African American 12.7 11.8
Other 5.3 3.9
Unknown 22.1 13.3
Number (%) of individuals undergoing a second imaging procedure within 1 year 304 (9.6) 1058 (6.6) <0.0001
Charlson Comorbidity Index (PCharlson) 2.46 2.56 <0.05
Number (%) where the repeat imaging is the same as the initial imaging procedure 134 (44.1) 988 (93.4) <0.0001
All values are percentages except age which is mean standard deviation.
CE-MRA, contrast-enhanced magnetic resonance angiography; DSA, digital subtraction angiography; PVD, peripheral vascular disease.
Table 2 Propensity score weights for choice of initial diagnostic imaging modality
Variable Logistic coefﬁcient Odds ratio P value
Chronic Renal Disease 1-yes/0-no 1.163 3.200 0.000
Amputation before imaging procedure 1-yes/0-no -0.505 0.604 0.001
Bypass before imaging procedure 1-yes/0-no 0.691 1.995 0.000
Angioplasty before imaging procedure 1-yes/0-no -1.114 0.328 0.000
Stent before imaging procedure 1-yes/0-no -1.520 0.219 0.000
Coronary artery disease 1-yes/0-no -0.236 0.790 0.000
Congestive heart failure 1-yes/0-no 0.284 1.329 0.000
Hypertension 1-yes/0-no -0.083 0.920 0.118
Diabetes 1-yes/0-no 0.129 1.137 0.009
Claudication 1-yes/0-no -0.677 0.508 0.000
PVD before imaging procedure 1-yes/0-no -1.072 0.342 0.000
White 1-yes/0-no -0.489 0.613 0.000
Black 1-yes/0-no -0.430 0.651 0.000
Age (years) -0.001 0.999 0.571
Gender (1 =male, 0 = female) -0.695 0.499 0.000
VA usual source of care 0.272 1.313 0.000
Charlson index (PCharlson) -0.072 0.930 0.000
Constant 0.404 1.499 0.024
Logistic dependent variable: 1, CE-MRA; 0, DSA.
CR-MRA, contrast-enhanced magnetic resonance angiography; DSA, digital subtraction angiography; PVD, peripheral vascular disease.
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Imaging Procedure Costs
The average unadjusted FY2004 cost in the VA system for a
CE-MRA imaging procedure was $470, although the average
unadjusted cost for a DSA imaging procedure was $1420, for a
net savings with an initial CE-MRA imaging procedure of $950.
The multivariate econometric analysis was utilized to determine
if 30- or 90-day treatment costs or complication costs were
signiﬁcantly different after adjusting for potential endogenous
choice of imaging modality, as described below.
Imaging Complications
As reported elsewhere [10], there were no statistically signiﬁcant
differences in mortality rates or in treatment complication rates
between the two initial diagnostic modalities with the exception
of hematoma rates (30-day rates: CE-MRA, 0.4%; DSA, 1.8%;
P < 0.0001). Because the average cost of treating a hematoma is
generally less than $9000 [13], this would add a maximum of $90
to the average cost of patients initially imaged with DSA.
However, using patient baseline characteristics and propensity
score adjustments as additional explanatory factors in a logistic
regression of vascular complication rates on initial imaging
modality showed that after adjusting for these factors, the rate of
vascular complications was not statistically signiﬁcant between
the two initial imaging modalities. Therefore, we conservatively
ignored treatment complication costs in assessing our estimates of
the 30-day and 90-day cost differences between CE-MRA and
DSA.
Imaging Modality Selection and Follow-up Procedure
Cost Differences between CE-MRA and DSA Patients
Initial CE-MRA imaging was signiﬁcantly more likely among
patients with prior renal disease or bypass surgery [odds ratio
(OR) > 1.99; P < 0.001], and less likely among patients with
prior amputation, PVD, claudication, or other cardiovascular
disease markers except for congestive heart failure (CHF)
(OR < 0.7; P < 0.001) (see Table 2).
Table 3 presents the propensity score-adjusted medical treat-
ment costs for 30 days and 90 days, after the initial imaging
procedure for CE-MRA and DSA patients. They show that
patient treatment costs were $3920 (30-day) and $5209 (90-day)
lower for CE-MRA patients than DSA patients, even after adjust-
ing for choice of imaging modality and other patient character-
istics (P < 0.0001). Using alternative methods for adjusting for
endogenous choice of initial imaging modality, 30-day treatment
costs were $3300–$4300 lower (P < 0.001) for imaging patients
with initial CE-MRA, depending on whether propensity scores,
Heckman selection bias coefﬁcients, or instrumental variables
were used to correct for endogenous selection bias (see Table 4).
The results were robust to whether costs, log-costs, or other
power transformations of the dependent cost variable were
utilized in the regressions.
Discussion
In this retrospective study of almost 20,000 VA patients undergo-
ing outpatient diagnostic imaging of the lower extremity, the rates
of follow-up imaging procedures and follow-up medical or surgi-
cal procedures within 30 or 90 days of the initial CE-MRAorDSA
was quite low. Complications following either of the two diagnos-
tic imaging methods were rare and not statistically different after
adjustment for selection bias. Even if we were to ascribe a 1%
greater occurrence of hematomas complication rates to DSA, this
would only increase our estimate of the cost savings associated
with CE-MRA by a maximum of $90 per patient. There was also
Table 3 30-day and 90-day procedure costs following diagnostic imaging with CE-MRA or DSA: propensity score adjusted
Explanatory variables
30-Day follow-up costs 90-Day follow-up costs
Beta coefﬁcient T-Ratio P-value Beta coefﬁcient T-Ratio P-value
(Constant) 6,966 3.187 0.001 13,553 4.811 0.000
Initial imaging (CE-MRA image = 1) -3,920 -12.104 0.000 -5,209 -12.479 0.000
Imaging propensity score -3,411 -0.774 0.439 -8,622 -1.518 0.129
White 1-yes/0-no 827 1.897 0.058 510 0.907 0.364
Black 1-yes/0-no 2,496 4.868 0.000 1,916 2.900 0.004
Age (years) -1 -0.074 0.941 -41 -2.674 0.008
Gender (1 =male, 0 = female) 791 0.850 0.395 3,049 2.541 0.011
VA usual source of care -1,684 -3.842 0.000 -2,785 -4.930 0.000
Chronic renal disease 1-yes/0-no 2,192 2.345 0.019 4,011 3.329 0.001
Amputation before imaging procedure 1-yes/0-no 13,720 16.984 0.000 14,183 13.621 0.000
Bypass before imaging procedure 1-yes/0-no 602 0.786 0.432 710 0.719 0.472
Angioplasty before imaging procedure 1-yes/0-no -1,458 -2.380 0.017 -3,353 -4.246 0.000
Stent before imaging procedure 1-yes/0-no -1,628 -2.445 0.015 -3,800 -4.426 0.000
Coronary artery disease 1-yes/0-no -940 -3.265 0.001 -1,517 -4.090 0.000
Congestive heart failure 1-yes/0-no 432 1.200 0.230 436 0.940 0.347
Hypertension 1-yes/0-no -1,206 -3.840 0.000 -1,100 -2.717 0.007
Diabetes 1-yes/0-no 1,079 3.776 0.000 2,030 5.510 0.000
Claudication 1-yes/0-no 1,755 1.642 0.101 3,242 2.354 0.019
PVD before imaging procedure 1-yes/0-no 1,075 1.193 0.233 3,036 2.615 0.009
Charlson Index (Pcharlson) 145.037 1.372 0.17 207.5307 1.523 0.128
CR-MRA, contrast-enhanced magnetic resonance angiography; DSA, digital subtraction angiography; PVD, peripheral vascular disease.
Table 4 30-day and 90-day episode treatment costs following initial primary care imaging CE-MRA versus DSA**
Unadjusted 30-day costs Unadjusted 90-day costs Adjusted 30-day costs* Adjusted 90-day costs* P value
Initial CE-MRA $2,611 $7,092 $6,752 $7,757
Initial DSA $6,108 $12,842 $10,073 $13,086
Difference $3,497 $5,749 $3,321 $3,013 <0.0001
*Multivariate regression: adjusted for image selection propensity score, white, black, age, gender, baseline disease history.
**P value for difference between CE-MRA and DSA 30-day/90-day episode costs (with/without adjustment).
CR-MRA, contrast-enhanced magnetic resonance angiography; DSA, digital subtraction angiography.
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no statistically signiﬁcant difference inmortality rates between the
two imaging groups.
Relative to DSA, CE-MRA imaging was associated with sub-
stantial treatment episode health care savings, beyond the $950
direct savings in imaging cost per initial procedure. These savings
estimates were robust to alternate model speciﬁcations and sta-
tistical corrections for endogenous selection of imaging modality.
Even setting aside the higher 30- and 90-day follow-up costs for
DSA patients, substituting CE-MRA for DSA among the 82% of
DSA patients not planning or requiring any follow-up procedures
within 30 days could have reduced outpatient imaging costs by
55%, and reduced VA system costs by $13.2 million ($950
savings per imaging procedure multiplied by 82% of the 16,961
DSA patients) over the six-year period. There was no evidence in
these data that there would be any offsetting clinical or cost
disadvantages for substituting CE-MRA among those patients
not anticipating any additional medical procedures within 30
days of the initial outpatient diagnostic imaging.
It is unclear why DSA patients used more procedures and
interventions than CE-MRA patients subsequent to the initial
outpatient imaging procedure, even after adjusting for patient
characteristics and imaging selection bias. It is possible that some
residual patient selection bias remains, with higher severity
patients receiving initial DSA rather than CE-MRA, but patients
with the highest level of severity are unlikely to receive additional
procedures because most interventions are ineffective in patients
with extreme peripheral artery occlusions.
Studies comparing outcomes following either MRA or DSA in
the evaluation of PAODare lacking. Studies assessing the accuracy
of both tests have concluded that both testing modalities are
comparable regarding the severity and location of the atheroscle-
rotic lesions [14]. Hematoma, arterial wall dissection, and throm-
bosis, are reported to occur up to 7.3% following DSA [15].
Our analysis is also limited by the retrospective nature of the
medical service utilization data that we were able to analyze. We
undertook a substantial medical chart review to ensure that our
ICD-9 and procedure code nets for diagnoses, follow-on proce-
dures, complications, etc., were valid and reliable. Nevertheless,
there is always some possibility that patients may have received
some relevant medical care services in non-VA facilities. More-
over, the VA patient population is atypical in terms of several
patient demographic characteristics and provider incentives. Nev-
ertheless, we suspect that any cost differences that we have iden-
tiﬁed are at least as likely to be found in other patient populations.
This study ﬁnds that there is substantial cost savings associ-
ated with the use of CE-MRA, relative to DSA as initial outpa-
tient imaging modality for PAOD patients. Although we were
able to identify substantial systematic differences in demographic
and medical history characteristics between patients receiving
CE-MRA and DSA, large majorities of both patient groups
received no follow-on medical procedures within 30 or 90 days,
suggesting that substantial cost savings could be realized with
the less-expensive CE-MRA imaging procedure. Moreover, it
appears as though treatment costs for patients initiating
CE-MRA imaging procedures are $3000–$5000 less than
patients initiating DSA imaging procedures, even after an adjust-
ment for available potential confounders and treatment selection
bias. These cost savings are substantially greater than those
reported in the literature [4,5,7–9].
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